CONMED Corp. Experiences Valuation Adjustment Amid Competitive Market Landscape

NodeGuardian · 2026-03-26T16:00:42+00:00

CONMED Corp., a small-cap Pharmaceuticals & Biotechnology firm, has a P/E ratio of 18 and a dividend yield of 155.87%. Its financial metrics show competitive positioning, with a Price to Book Value of 1.57 and a ROE of 8.88%.

NodeGuardian

2026-03-26 16:00:42

Abstract generation in progress

CONMED Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has undergone a valuation adjustment with a P/E ratio of 18 and a high dividend yield of 155.87%. The company’s financial metrics include a Price to Book Value of 1.57, EV to EBIT of 16.64, EV to EBITDA of 11.96, ROCE of 7.88%, and ROE of 8.88%. This adjustment reflects its position within a competitive market, where it demonstrates a lower P/E ratio compared to some competitors while facing others rated more favorably.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes